AR005651A1 - Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodo - Google Patents
Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodoInfo
- Publication number
- AR005651A1 AR005651A1 ARP970100192A ARP970100192A AR005651A1 AR 005651 A1 AR005651 A1 AR 005651A1 AR P970100192 A ARP970100192 A AR P970100192A AR P970100192 A ARP970100192 A AR P970100192A AR 005651 A1 AR005651 A1 AR 005651A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- expression
- fusion
- heterologous proteins
- escherichia coli
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 8
- 241000588724 Escherichia coli Species 0.000 title abstract 3
- 230000014509 gene expression Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000701533 Escherichia virus T4 Species 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 229940052778 neisseria meningitidis Drugs 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención está relacionada con la rama de la biotecnología y la ingeniería genética, particularmente con la expresión de proteínasheterólogas en microorganismos mediante su fusión , usando la tecnología del ADN recombinante, apépti dos bacterianos. Mediante ésta se proporciona unprocedimiento eficaz para la expresión en Escherichia coli de proteínas heterólogas como polipéptidos de fusión con vistas a su obtención con un altogrado de pureza, en cantidadescomercialmente útiles, y de forma que permita su inclusión en preparados vacunales destinados al uso de humanos. Para ello seemplea esencialmente una secuencia estabilizadora derivada de los primeros 47 aminoácidos del antígeno P64k de Neisseriameningitidis B:4 :P1.15. Enparticular se usa un plasmidio recombinante conteniendo dicha secuencia bajo el control del promotor triptófano de E. coli y el terminador de la transcripcióndel fago T4, incluyendo sitios de restricción que permiten laclonación en fase d e fragmentos de ADN codificantes para polipétidos de interés. El procedimientoes aplicable en la industria farmacéutica, para el desarrollo de sistemas de diagnóstico, de preparados vacunales, y en cualquier situación dondeseanecesaria la obtenci ón en grandes cantidades de proteínas heterólogas como polipéptidos de fusión de E:coli.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1996010A CU22559A1 (es) | 1996-01-17 | 1996-01-17 | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005651A1 true AR005651A1 (es) | 1999-07-14 |
Family
ID=5459182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100192A AR005651A1 (es) | 1996-01-17 | 1997-01-17 | Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodo |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6146635A (es) |
| EP (1) | EP0816506B1 (es) |
| JP (1) | JP4071282B2 (es) |
| KR (1) | KR100500782B1 (es) |
| CN (1) | CN1107115C (es) |
| AR (1) | AR005651A1 (es) |
| AT (1) | ATE198491T1 (es) |
| AU (1) | AU722317B2 (es) |
| BR (1) | BR9704641B1 (es) |
| CA (1) | CA2214840A1 (es) |
| CU (1) | CU22559A1 (es) |
| CZ (1) | CZ291097A3 (es) |
| DE (1) | DE69703813T2 (es) |
| DK (1) | DK0816506T3 (es) |
| EA (1) | EA000307B1 (es) |
| ES (1) | ES2157060T3 (es) |
| GR (1) | GR3035690T3 (es) |
| HU (1) | HUP9800730A3 (es) |
| IL (1) | IL121614A (es) |
| MX (1) | MX9707071A (es) |
| PT (1) | PT816506E (es) |
| WO (1) | WO1997026359A1 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| CN1224708C (zh) | 1998-01-14 | 2005-10-26 | 启龙股份公司 | 脑膜炎奈瑟氏球菌抗原 |
| GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| GB9818004D0 (en) * | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| JP2003523721A (ja) * | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| US6689879B2 (en) * | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
| AUPQ347199A0 (en) * | 1999-10-15 | 1999-11-11 | Csl Limited | Novel polypeptide fragments |
| ATE429643T1 (de) | 2000-07-12 | 2009-05-15 | Agensys Inc | Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann |
| WO2002018578A2 (en) | 2000-08-28 | 2002-03-07 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
| US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| AU2002318112B2 (en) | 2001-04-10 | 2007-12-06 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| WO2003004620A2 (en) | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| CU23245A1 (es) * | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
| GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| KR100447530B1 (ko) * | 2001-08-14 | 2004-09-08 | 한국과학기술원 | ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법 |
| US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| WO2003020876A2 (en) * | 2001-08-31 | 2003-03-13 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| EP2287186B1 (en) | 2001-09-06 | 2014-12-31 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| EP1565200A4 (en) | 2002-11-27 | 2009-06-24 | Agensys Inc | NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER |
| CA2860151A1 (en) | 2003-02-10 | 2004-08-26 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| AU2004263823B2 (en) | 2003-05-30 | 2008-09-18 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| US20050040037A1 (en) * | 2003-08-20 | 2005-02-24 | Walton Scott G. | Electron beam enhanced large area deposition system |
| CU23236A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
| CU23237A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
| EP2428522A1 (en) | 2004-05-28 | 2012-03-14 | Agensys, Inc. | Antibodies that bind to PSCA proteins for diagnosis of cancer |
| CN100518818C (zh) * | 2004-11-15 | 2009-07-29 | 中国人民解放军军事医学科学院生物工程研究所 | 一种预防和/或治疗消化系统肿瘤的疫苗 |
| WO2006105488A2 (en) | 2005-03-31 | 2006-10-05 | Agensys, Inc. | Antibodies and related molecules that bind to 161p2f10b proteins |
| CU23578A1 (es) | 2005-09-16 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal |
| CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
| US20110110974A1 (en) * | 2007-10-29 | 2011-05-12 | Erik Depla | Methods and kits for inducing a ctl response using a prime boost regimen |
| ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
| EP2530159A1 (en) * | 2011-06-03 | 2012-12-05 | Sandoz Ag | Transcription terminator sequences |
| WO2012170765A2 (en) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
| EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| CU24705B1 (es) | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| CU20230023A7 (es) | 2023-05-12 | 2024-12-09 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer |
| CN118126132B (zh) * | 2024-03-06 | 2024-08-16 | 广东医保药业有限公司 | 多肽及其与头孢噻肟舒巴坦的组合 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0472658A4 (en) * | 1989-05-19 | 1992-08-26 | Biotechnology Res & Dev | Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification |
| CU22302A1 (es) * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
-
1996
- 1996-01-17 CU CU1996010A patent/CU22559A1/es not_active IP Right Cessation
-
1997
- 1997-01-17 WO PCT/CU1997/000001 patent/WO1997026359A1/es not_active Ceased
- 1997-01-17 IL IL121614A patent/IL121614A/en not_active IP Right Cessation
- 1997-01-17 MX MX9707071A patent/MX9707071A/es not_active IP Right Cessation
- 1997-01-17 JP JP52556497A patent/JP4071282B2/ja not_active Expired - Fee Related
- 1997-01-17 US US08/930,917 patent/US6146635A/en not_active Expired - Fee Related
- 1997-01-17 CZ CZ972910A patent/CZ291097A3/cs unknown
- 1997-01-17 PT PT97901516T patent/PT816506E/pt unknown
- 1997-01-17 KR KR1019970706451A patent/KR100500782B1/ko not_active Expired - Fee Related
- 1997-01-17 EA EA199700244A patent/EA000307B1/ru not_active IP Right Cessation
- 1997-01-17 DE DE69703813T patent/DE69703813T2/de not_active Expired - Fee Related
- 1997-01-17 CN CN97190017A patent/CN1107115C/zh not_active Expired - Fee Related
- 1997-01-17 AU AU15396/97A patent/AU722317B2/en not_active Ceased
- 1997-01-17 ES ES97901516T patent/ES2157060T3/es not_active Expired - Lifetime
- 1997-01-17 HU HU9800730A patent/HUP9800730A3/hu unknown
- 1997-01-17 AR ARP970100192A patent/AR005651A1/es active IP Right Grant
- 1997-01-17 BR BRPI9704641-8A patent/BR9704641B1/pt not_active IP Right Cessation
- 1997-01-17 CA CA002214840A patent/CA2214840A1/en not_active Abandoned
- 1997-01-17 EP EP97901516A patent/EP0816506B1/en not_active Expired - Lifetime
- 1997-01-17 DK DK97901516T patent/DK0816506T3/da active
- 1997-01-17 AT AT97901516T patent/ATE198491T1/de not_active IP Right Cessation
-
2000
- 2000-07-10 US US09/612,925 patent/US6921809B1/en not_active Expired - Fee Related
-
2001
- 2001-04-02 GR GR20010400539T patent/GR3035690T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL121614A0 (en) | 1998-02-08 |
| KR19980703043A (ko) | 1998-09-05 |
| AU1539697A (en) | 1997-08-11 |
| DK0816506T3 (da) | 2001-05-21 |
| PT816506E (pt) | 2001-06-29 |
| CN1107115C (zh) | 2003-04-30 |
| US6921809B1 (en) | 2005-07-26 |
| HUP9800730A3 (en) | 1999-07-28 |
| EP0816506A1 (en) | 1998-01-07 |
| EA000307B1 (ru) | 1999-04-29 |
| CZ291097A3 (cs) | 1998-11-11 |
| DE69703813D1 (de) | 2001-02-08 |
| ATE198491T1 (de) | 2001-01-15 |
| CA2214840A1 (en) | 1997-07-24 |
| HUP9800730A2 (hu) | 1998-07-28 |
| AU722317B2 (en) | 2000-07-27 |
| BR9704641B1 (pt) | 2010-03-09 |
| EP0816506B1 (en) | 2001-01-03 |
| CU22559A1 (es) | 1999-05-03 |
| JPH11503617A (ja) | 1999-03-30 |
| KR100500782B1 (ko) | 2005-11-25 |
| EA199700244A1 (ru) | 1998-02-26 |
| GR3035690T3 (en) | 2001-07-31 |
| BR9704641A (pt) | 1998-06-09 |
| US6146635A (en) | 2000-11-14 |
| JP4071282B2 (ja) | 2008-04-02 |
| IL121614A (en) | 2006-10-31 |
| WO1997026359A1 (es) | 1997-07-24 |
| ES2157060T3 (es) | 2001-08-01 |
| CN1177982A (zh) | 1998-04-01 |
| MX9707071A (es) | 1997-11-29 |
| DE69703813T2 (de) | 2001-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005651A1 (es) | Proteina de fusion, vector de expresion para dicha proteina, cepa de escherichia coli que expresa dicha proteina, uso de dicha proteina, composicion de vacuna que comprende la proteina, metodo para la purificacion de la proteina y anticuerpo monoclonal empleado en el metodo | |
| Löwenadler et al. | A gene fusion system for generating antibodies against short peptides | |
| DE69229221D1 (de) | Expression rekombinanter proteine in attenuierten bakterien | |
| ATE353365T1 (de) | Neue b7-4 moleküle und deren verwendungen | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| DE3584053D1 (de) | Gentechnologisches verfahren zur herstellung von hirudinen und mittel zur durchfuehrung dieses verfahrens. | |
| AR062867A2 (es) | Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la | |
| DK175843B1 (da) | Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet | |
| ES2321058T7 (es) | Purificación de proteínas recombinantes fusionadas con epítopos múltiples | |
| Bikel et al. | Purification of biologically active simian virus 40 small tumor antigen. | |
| AR118942A1 (es) | Secuencias de selección dirigida para plataformas de visualización en endoesporas de paenibacillus | |
| CU22222A1 (es) | Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes | |
| Le et al. | Escherichia coli expression and refolding of E/K-coil-tagged EGF generates fully bioactive EGF for diverse applications | |
| Niitsu et al. | Subunit heterogeneity in ferritin | |
| Zemel-Dreasen et al. | Secretion and processing of an immunoglobulin light chain in Escherichia coli | |
| BR9714133A (pt) | ácido nucleico isolado, molécula do mesmo, sonda, vetor de expressão recombinante, célula, polipeptìdeo, proteìna de fusão formulação de vacina e processos para produzir um polipeptìdeo de h. pylori, para detctar a presença de um ácido nucleico de helicobacter em uma amostra, para tratar ou reduzir um risco de infecção por h. pylori em um indivìduo e para produzir uma formulação de vacina | |
| Lee et al. | Multicistronic IVT mRNA for simultaneous expression of multiple fluorescent proteins | |
| Kuchinke et al. | Fused lacZ genes code for di‐, tri‐and tetra‐beta‐galactosidase in Escherichia coli. | |
| KR101667023B1 (ko) | 무세포 단백질 합성 방법을 이용하여 생산된 항체의 세포질 내로의 유입을 간편하게 분석하는 방법 | |
| PE20010239A1 (es) | Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos | |
| KR100843634B1 (ko) | 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제 | |
| Portier | Physical localisation and direction of transcription of the structural gene for Escherichia coli ribosomal protein S15 | |
| EP0467676A2 (en) | Temperature-inducible secretion expression vectors and their use in prokaryotic cells | |
| Geli et al. | Recognition of the colicin A N-terminal epitope 1C11 in vitro and in vivo in Escherichia coli by its cognate monoclonal antibody | |
| WO2024163912A3 (en) | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |